|
|
Volumn 540, Issue 7631, 2016, Pages 15-16
|
|
Failed Alzheimer's trial does not kill leading theory of disease
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID PROTEIN;
SOLANEZUMAB;
ADUCANUMAB;
AMYLOID;
MONOCLONAL ANTIBODY;
DISEASE INCIDENCE;
DISEASE TREATMENT;
DRUG DEVELOPMENT;
HYPOTHESIS TESTING;
MENTAL HEALTH;
NERVOUS SYSTEM DISORDER;
PROTEIN;
ALZHEIMER DISEASE;
CLINICAL TRIAL (TOPIC);
DRUG MARKETING;
DRUG TREATMENT FAILURE;
GENETIC RISK;
HUMAN;
PREVENTION STUDY;
PRIORITY JOURNAL;
SHORT SURVEY;
THEORY;
BIOLOGICAL MODEL;
BIOSYNTHESIS;
CHEMISTRY;
DISEASE PREDISPOSITION;
DRUG INDUSTRY;
ECONOMICS;
IMMUNOLOGY;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
PATHOLOGY;
REPRODUCIBILITY;
UNCERTAINTY;
ALZHEIMER DISEASE;
AMYLOID;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS AS TOPIC;
DISEASE SUSCEPTIBILITY;
DRUG INDUSTRY;
HUMANS;
MODELS, BIOLOGICAL;
MOLECULAR TARGETED THERAPY;
REPRODUCIBILITY OF RESULTS;
UNCERTAINTY;
|
|
EID: 85000866102
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/nature.2016.21045 Document Type: Short Survey |
|
Times cited : (116)
|
|
References (0)
|